Menopause. Menopausal and female climacteric states
Conditions
Interventions
Intervention 1: The intervention group will receive 3 capsules containing 300 mg of powdered Cornus mas, daily, for 8 weeks. These capsules have been produced by Barij Essence Pharmaceutical Company.
Treatment - Drugs
Placebo
The intervention group will receive 3 capsules containing 300 mg of powdered Cornus mas, daily, for 8 weeks. These capsules have been produced by Barij Essence Pharmaceutical Company
Control group will receive 3 capsules containing 300 mg starch powder as placebo, daily, for 8 weeks, produced by Barij Essence Pharmaceutical Company
Sponsors
Vice Chancellor for research, Iran University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
45 Years to 60 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: at least 12 month of amenorrhea; No history of allergies to cornus mas fruit and products; No HRT or other menopausal treatments during last 6 months; no intake of progesterone; No intake of medicines which have effect on blood sugar, blood pressure, or blood lipids; No abnormal vaginal bleeding; No kidney or liver active illness or Inflammation (No history of Malignity); No consumption of soy or vegan diet; No history of thromboembolism; No consumption of Nutritional supplement in the past 3 months (Omega 3 and antioxidant); No drinking alcohol or smoking habit ; ability to recognize and understand the purpose of study; ability to read and write Exclusion criteria: history of allergies to cornus mas fruit and products; HRT or other menopausal treatments during last 6 months; Hysterectomy; intake of progesterone; intake of medicines which have effect on blood sugar, blood pressure, or blood lipids; abnormal vaginal bleeding; kidney or liver active illness or Inflammation ( history of Malignity); consumption of soy or vegan diet; history of thromboembolism; consumption of Nutritional supplement in the past 3 months (Omega 3 and antioxidant); drinking or smoking habit
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Fasting blood sugar. Timepoint: before intervention, after intervention. Method of measurement: biochemical tests.;Serum fasting insulin. Timepoint: Before intervention, after intervention. Method of measurement: Biochemical tests.;Serum fasting cholestrol. Timepoint: Before intervention, after intervention. Method of measurement: Biochemical tests.;Serum fasting triglycerid. Timepoint: Before intervention, after intervention. Method of measurement: Biochemical tests.;LDL cholestrol. Timepoint: Before intervention, after intervention. Method of measurement: Biochemical tests.;HDL cholestrol. Timepoint: Before intervention, after 2 month intervention. Method of measurement: Biochemical tests.;ApoA1. Timepoint: Before intervention, after intervention. Method of measurement: Biochemical tests.;ApoB100. Timepoint: Before intervention, after intervention. Method of measurement: Biochemical tests.;Leptin. Timepoint: Before intervention, after intervention. Method of measurement: Biochemical tests. | — |
Secondary
| Measure | Time frame |
|---|---|
| Fibrinogen. Timepoint: Before intervention, after intervention. Method of measurement: Biochemical tests. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr Naheed Aryaeian
Iran University of Medical Sciences
Outcome results
None listed